Journal article icon

Journal article

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: Outcomes from TECOS.

Abstract:

Aims

To characterize the incidence of diabetes-associated complications and assess the safety of sitagliptin in participants with chronic kidney disease (CKD) in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Materials and Methods

For participants with baseline eGFR measurements (n=14,528), baseline characteristics and safety outcomes were compared for the CKD cohort (eGFR <60 mL/min per 1.73 m2) versus those without CKD. Within the CKD ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1111/dom.12983

Authors


Suryawanshi, S More by this author
Stevens, SR More by this author
Cornel, JH More by this author
Expand authors...
Merck and Co., Inc. More from this funder
Publisher:
Wiley Publisher's website
Journal:
Diabetes, Obesity and Metabolism Journal website
Volume:
19
Issue:
11
Pages:
1587-1593
Publication date:
2017-04-22
Acceptance date:
2017-04-19
DOI:
EISSN:
1463-1326
ISSN:
1462-8902
Pubs id:
pubs:692124
URN:
uri:eccdb0d2-fd12-45a5-ba50-9e39d19d53c7
UUID:
uuid:eccdb0d2-fd12-45a5-ba50-9e39d19d53c7
Local pid:
pubs:692124
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP